Aulos Bioscience Advances AU-007 to Phase 2 Portion of Phase 1/2 Study Evaluating Computationally Designed IL-2 Antibody for Treatment of Solid Tumors | Biolojic Design

Categories: News | Published On: December 18, 2023 | Written by Brandon Tilley |

Aulos Bioscience Advances AU-007 to Phase 2 Portion of Phase 1/2 Study Evaluating Computationally Designed IL-2 Antibody for Treatment of Solid Tumors

More News

Biolojic Design Appoints Roger Waltzman as Chief Medical Officer
Read More
Teva and Biolojic Design Initiate IND-enabling Studies of BD9, a Multibody Designed to Explore the Treatment of Atopic Dermatitis and Asthma
Read More

BUSINESS AND MEDIA INQUIRIES

Micah Pearlman
micah@biolojic.com